Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70096 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Fianne Sips und 9 weiteren Autor:innen. Beteiligte Einrichtung: InSilicoTrials Technologies BV, 's-Hertogenbosch, the Netherlands. Hauptthemen laut MEDLINE: Drug Development, Machine Learning, Rare Diseases, Computer Simulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Drug development in pediatric rare diseases is complicated by practical and ethical constraints on clinical trial design, stemming from small, highly heterogeneous, and vulnerable patient populations. Virtual patients (VPs) created with machine‐learning (ML), mechanistically driven computational approaches, or hybrids thereof, have the potential to expedite and maximize the impact of trials. We discuss the potential of VPs to transform the efficiency and impact of clinical trials in pediatric rare diseases, based on adult and pediatric examples.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- InSilicoTrials Technologies BV, 's-Hertogenbosch, the Netherlands.
- InSilicoTrials Technologies Spa, Trieste, Italy.
- Fondazione the Microsoft Research - University of Trento Centre for Computational and Systems Biology (COSBI), Rovereto, Italy.
- Axoltis Pharma, Bioparc Laennec, Lyon, France.
- Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
ORCID-Profile: Marco Virgolin, Giuseppe Pasculli, Federico Reali, Alessio Paris, Annette Janus, Daniel Röshammar, Luca Marchetti, Jane Knöchel
Zitieren
APA
Sips, F., Virgolin, M., Pasculli, G., Reali, F., Paris, A., Janus, A., Godfrin, Y., Röshammar, D., Marchetti, L., & Knöchel, J. (2025). Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70096
Vancouver
Sips F, Virgolin M, Pasculli G, Reali F, Paris A, Janus A, et al. Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70096
BibTeX
@article{Sips2025,
author = {Sips, Fianne and Virgolin, Marco and Pasculli, Giuseppe and Reali, Federico and Paris, Alessio and Janus, Annette and Godfrin, Yann and Röshammar, Daniel and Marchetti, Luca and Knöchel, Jane},
title = {Transforming Pediatric Rare Disease Drug Development: Enhancing Clinical Trials and Regulatory Evidence With Virtual Patients},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70096}
}
EUVIMED